Author

Hans L. A. Nienhuis

Observed names: H. L. A. Nienhuis, H. L. Nienhuis, H.L.A. Nienhuis, HANS L.A. NIENHUIS, HLA Nienhuis, Hans L A Nienhuis, Hans L. Nienhuis, Hans L.A. Nienhuis, Hans LA Nienhuis, Hans La Nienhuis, Hans Nienhuis, Nienhuis, H L A, Nienhuis, H. L. A., Nienhuis, H.L.A., Nienhuis, Hans, Nienhuis, Hans L. A.

Institutions: University Medical Center Groningen, University of Groningen

Observed institutions: University Medical Center Groningen, Radboud University Nijmegen, University of Groningen, Erasmus MC, Radboud University Medical Center, University Medical Center Utrecht, Hospital Clínic de Barcelona, Azienda Ospedaliero-Universitaria Careggi, Sint Maartenskliniek, Amsterdam UMC Location Vrije Universiteit Amsterdam

ORCID: 0000-0003-3974-6830

Observed ORCID: 0000-0003-3974-6830

OpenAlex ID: A5015811637

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

2020 · David Adams, Michael Polydefkis, et al. · The Lancet Neurology · 159

The Prevalence and Management of Systemic Amyloidosis in Western Countries

2016 · Hans L.A. Nienhuis, Johan Bijzet, et al. · Kidney Diseases · 135

Causes of AA amyloidosis: a systematic review

2019 · Anne Floor Brunger, Hans L. A. Nienhuis, et al. · Amyloid · 129

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

2022 · Angela Dispenzieri, Teresa Coelho, et al. · Orphanet Journal of Rare Diseases · 87

Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis

2021 · Angelo Giuseppe Caponetti, Claudio Rapezzi, et al. · JACC Heart Failure · 79

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

2021 · Jose Nativi-Nicolau, Alfonso Siu, et al. · JACC CardioOncology · 62

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis

2019 · Maarten P van den Berg, Bart A Mulder, et al. · European Heart Journal · 60

Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis

2020 · Jelger Louwsma, Anne F. Brunger, et al. · Amyloid · 57

Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis

2012 · HA Martens, HLA Nienhuis, et al. · Lupus · 56

Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts

2008 · H. L. Nienhuis, K. de Leeuw, et al. · Lara D. Veeken · 56

AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis

2009 · Hans L. A. Nienhuis, Johanna Westra, et al. · Autoimmunity · 54

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

2022 · Courtney M. Campbell, Samantha LoRusso, et al. · Cardiology and Therapy · 50

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

2021 · Márcia Waddington-Cruz, Jonas Wixner, et al. · Neurology and Therapy · 48

Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy

2025 · David Adams, Jonas Wixner, et al. · JAMA Neurology · 40

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide

2017 · Sebastiaan H.C. Klaassen, Jasper Tromp, et al. · The American Journal of Cardiology · 31

The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study

2016 · John H. Meertens, Hans L. Nienhuis, et al. · PLoS ONE · 27

Enhanced endothelium-dependent microvascular responses in patients with Wegener's granulomatosis.

2007 · Hans L A Nienhuis, Karina de Leeuw, et al. · PubMed · 26

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

2023 · Juan González-Moreno, Angela Dispenzieri, et al. · Cardiology and Therapy · 25

Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?

2023 · H. S. A. Tingen, A. Tubben, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 21

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

2023 · Laura Obici, Senda Ajroud-Driss, et al. · Neurology and Therapy · 21

The relation between C-reactive protein and serum amyloid A in patients with autoinflammatory diseases

2022 · G. E. Legger, C. W. E. Dermer, et al. · Pediatric Rheumatology · 21

Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review

2024 · Milou Berends, Hans Nienhuis, et al. · International Journal of Molecular Sciences · 18

Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis

2024 · Milou Berends, Anne F. Brunger, et al. · Amyloid · 18

Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?

2018 · Daphne L. Jonker, Bouke P.C. Hazenberg, et al. · Journal of Nuclear Cardiology · 18

Prevalence of Wild-Type Transthyretin Amyloidosis in a Prospective Heart Failure Cohort with Preserved and Mildly Reduced Ejection Fraction: Results of the Amylo-VIP-HF Study

2024 · Alwin Tubben, Hendrea S.A. Tingen, et al. · European Journal of Heart Failure · 15

Works count: 95

Citation count: 1,514

H-index: 21

I10-index: 31